This trial will test if a new eye drop can reduce the need for reading glasses in people with presbyopia.
1 Primary · 4 Secondary · Reporting Duration: Month 2 and Month 3
3 Treatment Groups
0.1% STN1013600 ophthalmic solution
1 of 3
0.3% STN1013600 ophthalmic solution
1 of 3
Placebo (Vehicle) ophthalmic solution
1 of 3
75 Total Participants · 3 Treatment Groups
Primary Treatment: 0.1% STN1013600 ophthalmic solution · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 47 - 55 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there an opportunity for me to join this clinical research study?
"To become a part of this medical trial, volunteers must be between 47 and 55 years old with presbyopia. The team hopes to enlist up to 75 participants in total." - Anonymous Online Contributor
Does this clinical trial permit elderly individuals over the age of 85 to participate?
"Participants for this medical study must be aged 47 and over, but below the age of 55." - Anonymous Online Contributor
Are there any vacancies for prospective participants in this research?
"Per information on clinicaltrials.gov, this research is presently enrolling patients; it was initially publicized on December 21st 2022 and its particulars were most recently revised January 12th 2023." - Anonymous Online Contributor
What is the aggregate participation in this clinical experiment?
"Affirmative. The clinicaltrials.gov website indicates that this trial is actively recruiting patients - it was initially posted on December 21st 2022 and has been modified most recently on January 12th 2023. 75 participants are needed for the study at two separate sites." - Anonymous Online Contributor
What potential risks are associated with the application of 0.1% STN1013600 ophthalmic solution?
"Our assessment at Power rates 0.1% STN1013600 ophthalmic solution to be safe with a score of 2 since it is currently in Phase 2 trials; there are observations indicating its safety but no evidence showing efficacy yet." - Anonymous Online Contributor